assist
directorgener
health
system
innov
mariepaul
kieni
open
consult
frame
meet
context
broader
blueprint
r
prepared
emerg
respons
known
prioriti
pathogen
first
author
report
present
landscap
analysi
merscov
diagnost
prevent
therapeut
highlight
major
gap
advanc
ongo
research
productdevelop
activ
baselin
analysi
summar
report
written
consult
access
websit
http
wwwwhointcsrresearchanddevelopmentmerslandscapepdf
overview
seri
present
describ
current
knowledg
merscov
epidemiolog
alreadi
broad
consensu
within
scientif
commun
dromedari
camel
main
anim
reservoir
sourc
zoonot
transmiss
human
howev
dynam
transmiss
event
dromedari
human
human
poorli
understood
although
studi
demonstr
individu
close
frequent
contact
ie
occup
expos
dromedari
much
higher
risk
merscov
infect
gener
remain
unclear
rout
exposur
mediat
viral
transmiss
effici
sinc
recogn
introduct
entrench
merscov
human
popul
major
merscov
outbreak
occur
nosocomi
although
surveil
program
observ
studi
enhanc
infectioncontrol
system
priorit
implement
throughout
middl
east
still
wide
variabl
across
region
reach
surveil
effort
depth
case
investig
adher
infectioncontrol
protocol
improv
effort
requir
polit
coordin
across
multipl
sector
within
countri
highest
risk
futur
outbreak
streamlin
commun
engag
affect
commun
crossvalid
diagnost
alreadi
use
develop
earli
stage
infect
merscov
clinic
distinguish
type
respiratori
infect
thu
current
case
definit
merscov
infect
base
laboratori
develop
harmon
sensit
specif
easili
administ
diagnost
assay
crucial
success
surveil
system
epidemiolog
studi
efficaci
assess
clinic
trial
one
princip
challeng
develop
use
diagnost
assay
depend
high
level
viru
replic
thu
detect
infect
sever
day
viral
exposur
time
individu
infecti
pose
great
risk
other
speak
issu
sever
particip
survey
diagnost
use
comment
current
util
futur
viabil
clinic
research
purpos
nucleic
test
naat
current
gold
standard
merscov
diagnost
although
test
becom
substanti
easier
implement
perform
still
depend
specimen
qualiti
technician
train
environment
contamin
easili
confound
accur
interpret
result
serolog
base
immunofluoresc
immunochromatographi
enzymelink
immunosorb
liveviru
pseudoviru
perform
characterist
provid
benefit
naat
form
easier
implement
function
relev
perform
assay
particularli
respect
merscov
depend
administ
natur
histori
diseas
detail
understand
key
featur
clinic
cours
merscov
infect
therefor
need
inform
optim
exist
assay
develop
nextgener
diagnost
gener
agre
even
absenc
data
urgent
need
rapid
pointofcar
diagnost
human
anim
popul
suggest
made
develop
commerci
least
adequ
dipstick
immunochromatograph
assay
suitabl
use
livestock
human
confirmatori
test
posit
result
human
also
recommend
moreadvanc
diagnost
realtim
reversetranscriptas
polymeras
chain
reaction
assay
develop
part
multival
respiratori
panel
also
need
coordin
effort
sequenc
circul
virus
correl
data
phenotyp
outcom
viral
fit
virul
relationship
surfac
spike
merscov
protein
gener
call
develop
commerci
test
qualiti
assur
exist
assay
although
work
alreadi
valid
diagnost
test
essenti
execut
interpret
epidemiolog
studi
better
defin
viral
reservoir
transmiss
dynam
correl
protect
current
licens
treatment
merscov
discoveri
antivir
merscov
limit
repurpos
compound
alreadi
licens
develop
diseas
experiment
treatment
use
sporad
outbreak
use
sarscov
sarscov
epidem
howev
use
treatment
ribavirin
interferon
corticosteroid
yield
littl
clinic
benefit
despit
show
efficaci
nonhuman
primat
nhp
highthroughput
screen
larg
librari
uncov
pharmaceut
agent
across
sever
class
inhibit
merscov
replic
vitro
improv
surviv
marmoset
investig
agent
also
repurpos
infecti
diseas
ebola
viru
diseas
potenti
use
merscov
data
present
antivir
furthest
along
develop
adenin
analog
incorpor
viral
rna
disrupt
replic
shown
protect
nhp
ebola
viru
diseas
advanc
phase
doseescal
far
activ
merscov
test
cell
line
antibodi
monoclon
polyclon
eclips
antivir
focu
merscov
therapeut
r
initi
convalesc
plasma
administr
use
emerg
infect
outbreak
seen
potenti
expediti
effect
mean
postexposur
prophylaxi
set
cluster
region
protocol
develop
ultim
could
implement
owe
lack
suffici
convalesc
meanwhil
differ
formul
polyclon
antibodi
deriv
transchromosom
human
bovin
model
move
forward
develop
prophylact
therapeut
use
polyclon
prepar
significantli
reduc
viral
lung
titer
mice
intranas
transduc
adenovir
vector
express
human
merscov
cognat
protein
receptor
ref
howev
note
sever
expert
therapeut
studi
conduct
thu
far
anim
may
relev
human
outbreak
given
product
administ
hour
challeng
probabl
symptom
human
would
appear
among
product
research
pre
postexposur
prophylaxi
monoclon
antibodi
mab
target
receptorbind
domain
rbd
furthest
along
productdevelop
tabl
present
meet
although
repres
group
develop
merscov
mab
present
data
origin
potenc
breadth
anim
efficaci
respect
mab
common
theme
emerg
session
whole
discuss
follow
antibodi
develop
target
rbd
potenti
viral
escap
one
mab
thu
greater
effort
monitor
circul
strain
assess
viral
evolut
ii
defin
measur
phenotyp
correl
viral
sequenc
iii
investig
use
combin
mab
polyclon
sera
overcom
potenti
emerg
therapeut
resist
iv
studi
serum
human
survivor
better
understand
respons
natur
infect
develop
refer
reagent
global
develop
coronaviru
vaccin
fade
aftermath
sarscov
pandem
sinc
gain
renew
momentum
face
current
merscov
outbreak
session
start
broad
overview
vaccinedevelop
pipelin
stress
vaccin
fail
advanc
beyond
phase
test
lack
interest
funder
limit
industri
support
realm
emerg
infecti
diseas
suspect
known
pandem
potenti
government
agenc
nongovernment
organ
might
key
role
develop
intervent
diseas
provid
strong
incent
privatesector
invest
still
relev
public
health
global
secur
current
dozen
vaccin
candid
preclin
develop
tabl
seven
group
present
product
meet
develop
base
immunogen
design
surfac
glycoprotein
primari
target
neutral
antibodi
natur
merscov
multipl
platform
use
produc
includ
limit
present
meet
liveattenu
virus
dna
vector
protein
subunit
viral
vector
ie
adenoviru
modifi
vaccinia
viru
ankara
measl
viru
sever
product
present
demonstr
protect
least
one
anim
model
although
vaccin
candid
pipelin
develop
human
use
two
vaccin
test
camel
effect
would
interrupt
transmiss
viru
human
success
exampl
onehealth
human
anim
environment
concern
describ
vaccin
hendra
viru
one
lesson
learn
hendra
experi
preclin
develop
animalmodel
test
relev
smaller
anim
model
extens
efficaci
trial
commenc
largeranim
target
popul
hors
case
merscov
dromedari
camel
downselect
vaccin
candid
smaller
anim
increas
likelihood
success
larg
anim
crucial
cost
much
higher
logist
challeng
much
greater
latter
model
addit
lesson
take
previou
experi
anim
vaccin
human
health
engag
affect
popul
educ
potenti
benefit
risk
vaccin
anim
ie
camel
commun
one
difficulti
face
develop
effect
vaccin
merscov
absenc
anim
model
recapitul
pathogenesi
natur
histori
sever
human
diseas
two
present
robust
discuss
center
limit
field
sever
mous
model
transgen
human
protein
receptor
despit
manifest
clinic
diseas
data
transgen
mice
might
need
supplement
larger
anim
model
clinic
advanc
ultim
licens
semipermiss
nhp
use
anim
surrog
vaccineefficaci
test
thu
clear
whether
either
rhesu
marmoset
nhp
model
serv
accur
proxi
human
diseas
given
knowledg
human
patholog
merscov
infect
limit
singl
develop
relev
anim
model
requir
parallel
investig
elucid
viru
pathogenesi
human
addit
concern
vaccin
develop
new
coronaviru
may
induc
antibodydepend
enhanc
infect
eosinophil
pulmonari
infiltr
observ
among
mice
vaccin
viruslik
particl
vlp
sarscov
howev
none
vaccin
current
develop
merscov
includ
vlp
killedinactiv
platform
roadmap
merscov
r
supplementari
note
focu
vaccin
indic
popul
purpos
prioriti
perspect
three
broad
indic
vaccin
discuss
first
two
indic
human
use
includ
singledos
vaccin
deploy
individu
acut
risk
outbreak
twodos
vaccin
induc
durabl
protect
continu
risk
camel
handler
healthcar
worker
third
vaccin
indic
propos
dromedari
particularli
juvenil
camel
pose
greater
risk
older
camel
transmit
viru
human
endpoint
veterinari
vaccin
like
reduct
prevent
viral
shed
rather
steril
immun
despit
great
potenti
camel
vaccin
interrupt
epidem
gap
fund
develop
camel
vaccin
convent
sourc
support
veterinari
vaccin
one
reason
may
merscov
vaccin
camel
would
use
differ
convent
veterinari
vaccin
usual
anim
vaccin
prevent
ill
death
within
veterinari
popul
case
merscov
camel
vaccin
campaign
howev
primari
intent
prevent
infect
diseas
human
popul
import
shore
fund
camel
vaccin
option
may
fastest
development
regulatori
rout
toward
licens
product
prevent
human
merscov
infect
death
r
roadmap
use
success
mani
sector
largescal
collabor
effort
requir
deliv
outcom
relat
innov
develop
new
product
process
essenti
start
clearli
articul
understand
goal
market
product
highlevel
prioriti
area
first
identifi
agreement
specif
activ
decid
also
crucial
first
map
baselin
knowledg
gap
develop
strateg
plan
address
defici
also
requir
assess
capac
need
support
activ
project
manag
implement
structur
subsequ
establish
pursu
agreedupon
activ
reach
goal
exampl
process
found
malaria
vaccin
technolog
roadmap
culmin
firstgener
malaria
vaccin
catalyz
develop
secondgener
product
http
wwwwhointimmunizationtopicsmalariavaccineroadmapen
meet
four
strateg
goal
agre
upon
principl
first
establish
surveil
network
coronaviru
laboratori
earli
warn
system
identifi
circul
speci
strain
anim
popul
new
outbreak
human
popul
emerg
strain
popul
second
acquir
better
understand
merscov
pathogenesi
natur
histori
veterinari
human
epidemiolog
third
develop
manufactur
test
licens
use
improv
diagnost
prevent
therapeut
enabl
interrupt
transmiss
human
dromedari
camel
human
fourth
perhap
import
global
donor
commun
establish
mechan
provid
lineofsight
manufactur
preclin
proofofconcept
studi
postlicens
procur
merscov
product
initi
publichealth
financi
model
emerg
pathogen
priorit
blueprint
process
seri
activ
priorit
divid
follow
categori
basic
translat
epidemiolog
social
research
ii
crosscut
product
develop
includ
refin
relev
anim
model
develop
refer
reagent
design
tool
method
ration
priorit
product
iii
improv
diagnost
iv
therapeut
mab
polyclonalantibodi
prepar
v
vaccin
human
camel
vi
capac
develop
vii
polici
commerci
develop
consult
potenti
fund
stakehold
biomed
advanc
research
develop
author
barda
us
nation
institut
health
nih
wellcom
trust
european
commiss
intern
vaccin
initi
among
other
broader
merscov
research
commun
includ
publichealth
offici
manufactur
regul
productdevelop
partnership
draft
roadmap
post
public
consult
websit
throughout
month
februari
final
may
http
wwwwhointcsrresearchanddevelopmentroadmapconsultationen
ebola
epidem
west
africa
reveal
great
potenti
pernici
defici
within
exist
mechan
rapid
medicalproduct
develop
deploy
aftermath
epidem
global
health
commun
coalesc
around
realiz
multifacet
plan
requir
respond
quickli
effici
next
outbreak
current
develop
r
blueprint
prepar
respons
follow
highlight
merscov
case
studi
although
global
coordin
result
matur
preclin
pipelin
novel
intervent
merscov
product
develop
along
faster
normal
timelin
greater
invest
multipl
agenc
develop
manufactur
preclin
clinic
test
well
prepar
time
efficaci
test
affect
popul
incid
diseas
rise
sharpli
global
commun
take
lesson
recent
ebola
crisi
appli
current
zika
viru
outbreak
prepar
potenti
anoth
region
epidem
broader
pandem
stakehold
research
product
develop
emerg
pathogen
must
set
sound
strategi
best
target
invest
anticip
futur
outbreak
current
consult
first
step
toward
end
open
forum
global
dialogu
publichealth
agenc
scientist
product
develop
funder
engag
joint
plan
merscov
r
activ
